OncoMatch/Clinical Trials/NCT06581640
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Is NCT06581640 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CAR-T treatment for multiple myeloma.
Treatment: CAR-T treatment — To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) overexpression (positive)
Flow cytometry or histology confirms positive BCMA expression in myeloma cells
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: BCMA-targeted therapy
Previously received treatment targeting BCMA
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within the last 6 weeks
Underwent autologous hematopoietic stem cell transplantation within the last 6 weeks
Cannot have received: experimental drug
Exception: within the last 3 months
Received other experimental drug treatments within the last 3 months
Lab requirements
Blood counts
ALC ≥0.5 ×10^9/L, PLT >30×10^9/L, Hb >80 g/L
Kidney function
creatinine clearance rate >30 mL/min
Liver function
ALT and AST ≤2.5×ULN, those with liver involvement can be relaxed to ≤5×ULN; serum total bilirubin <34 μmol/L
Cardiac function
heart ejection fraction (EF) ≥40%, no pericardial effusion and significant arrhythmia; indoor SpO2 ≥92%
The patient has good liver, kidney, heart, and lung function: ALT and AST ≤2.5×ULN, those with liver involvement can be relaxed to ≤5×ULN; serum total bilirubin <34 μmol/L; creatinine clearance rate >30 mL/min; heart ejection fraction (EF) ≥40%, no pericardial effusion and significant arrhythmia; indoor SpO2 ≥92%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06581640 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCMA-targeted therapy, autologous hematopoietic stem cell transplantation, experimental drug disqualifies patients from enrollment.
Does this trial require TNFRSF17?
Yes, TNFRSF17 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages